Search results
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. via Yahoo Finance· 2 years agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?
Simply Wall St. via Yahoo Finance· 3 months agoWe feel now is a pretty good time to analyse Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) business as...
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
Simply Wall St. via Yahoo Finance· 2 months agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Simply Wall St. via Yahoo Finance· 7 months agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Atossa: Acquiring CAR-T Company Would Be a Great Move, Says Analyst
TipRanks via Yahoo Finance· 2 years agoAccording to a recent 8-K filed by Atossa Therapeutics (ATOS), the biotech has signed a letter...
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Simply Wall St. via Yahoo Finance· 1 year agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Zacks via Yahoo Finance· 5 months agoThe Medical group has plenty of great stocks, but investors should always be looking for companies...
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Zacks via Yahoo Finance· 3 weeks agoAtossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that...
Q2 2023 Atossa Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 9 months agoParticipants Eric Van Zanten; VP, IR & Public Relations; Atossa Therapeutics, Inc. Steven Quay; Chairman of the Board & CEO; Atossa Therapeutics, Inc. Greg Weaver; CFO; Atossa Therapeutics, ...
Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysis
GuruFocus.com via Yahoo Finance· 1 month agoOperating Expenses: Increased to $31.4 million in 2023, up from $27.7 million in 2022. Research and Development (R&D) Expenses: Rose to $17.3 million, with significant investment in clinical ...
